Stansberry’s Investment Advisory Releases Next 4X Jump in Biotech Stock Report

Looking to invest in a company that specializes in the medical sector? Stansberry Research’s publisher, Brett Aitken affirms that there is one company’s stock that is expected to soar by 100% in a matter of days.

His reasoning is that the firm under consideration will be releasing the first drug of its kind to lead a “$1 trillion drug franchise.” What is this drug and what was it designed to treat? While the drug remains undisclosed, it has been shared that that the drug has passed a number of trials and can aid in treating Alzheimer’s disease.

Want in on the investment opportunity at hand? To gain access to this ground-breaking drug and its respective firm, individuals will have to become a member of Stansberry’s Investment Advisory.

See Stansberry Innovations Report Here

What is Stansberry’s Investment Advisory?

Stansberry’s Investment Advisory is a monthly newsletter that allows investors make money from promising trends and impactful economic forces that are constantly introduced in the market. In the provided portfolio, investors will be required to hold anywhere between 20 and 30 positions – all of which are deemed very low in terms of the conservative scale.

In addition, investors looking to hold for a short term cannot expect much, as this newsletter focuses primarily on long recommendations (i.e. up to one year).

Who is Porter Stansberry?

Porter Stansberry is the founder of Stansberry Research with the firm’s flagship publication, Stansberry’s Investment Advisory. Before launching this firm, he was considered the first American to write one of the oldest financial newsletters (i.e. the Fleet Street Letter). He’s also known for a number of his predictions, primarily that of the mortgage meltdown.

What will I get by becoming a member of Stansberry’s Investment Advisory?

The moment an individual becomes a member of Stansberry’s Investment Advisory, the following reports will be sent out immediately:

The Next 4X Jump in Biotech: How to Profit Off the Most Valuable Unknown Drug in the World

This report will include everything there is to know in regard to the aforementioned treatment such as the company behind it, how one can invest in it, how the FDA might respond to this drug, the right price to pay, the best time to sell and many others.

Bonus Report #1: The Ultimate Trump Trade

In The Ultimate Trump Trade, members will come to learn of President Trump’s least favorite company in America whose share is expected to soar. Based on the advertisement, this might include a gun stock, but this has not been explicitly stated.

Bonus Report #2: The Tax-Free Way to Make 500% Gains in America Today

This second report urges investors to shy away from the U.S dollar and consider an investment that could bring five times more gains if a long-term position is held. In addition, this can be achieved without having to worry about taxes.

Bonus Report #3: Ten U.S. Companies That Will Soon Collapse

As the title gives it away, Stansberry will disclose the top ten list of companies that are anticipated to suffer as America’s debt continues to climb. In fact, he predicts that many are likely to go bankrupt given their poor profits and cash flow.

Other perks include:

  • 12 monthly issues including recommendations and current portfolio
  • The Stansberry Digest, which includes notes on diverse situations that impact the current markets
  • Email updates as needed

How much does the Stansberry’s Investment Advisory membership cost?

The current going price of the Stansberry’s Investment Advisory is $49 for a full year of access. In addition, a 30-day money-back guarantee is in place as well. Should the editor’s approaches not meet one’s expectations, a refund can be requested by contacting customer service at:

Bear in mind that the $49 rate only applies to the first year, every year thereafter will cost $199 (plus applicable taxes).

What are existing members saying about Stansberry’s Investment Advisory?

Based on roughly 394 members who’ve voted on Stock Gumshoe, members seem to have been generally satisfied with the service. In particular, many were happy with customer service, the quality of analyses provided, the value of the service and the investment performance.

Final Thoughts

Stansberry’s Investment Advisory is a newsletter that notifies members of investment opportunities in emerging markets. Even though this service does include some short recommendations, it is more appropriate for anyone who is looking to take long positions (at least one year) to make profits.

As for the editor, Porter Stansberry seems to have picked highly performing stocks up until now as members have expressed satisfaction. Most of all, this service is currently priced at $49 for the first year, which is relatively cheap in comparison to other existing newsletters.

To learn more about what Stansberry’s Investment Advisory has to offer, click here, or click the button below to see Stansberry Research's Innovations Report today.

See Stansberry Innovations Report Here

Andrew: Andrew is the Senior Writer at GainBitcoin. He covers news on Bitcoin and Altcoins. He has worked with some of the most popular websites in the cryptocurrency and finance industry. Apart from journaling, traveling around the world in search for what's next is how he rolls. To get in touch with Andrew for news tips, email him at andrew@gainbitcoin.com.